Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Fosun Antekin

Request full access

Developer of mRNA and conjugate vaccine technologies.

Chengdu, ChinaFounded 2012Biotech & Life Sciences

About Fosun Antekin

Fosun Adgenvax Biopharmaceutical is a controlling subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., focused on the research, development, and commercialization of vaccines. The company is a key part of Fosun Pharma's vaccine business segment and has been preparing for a potential spin-off listing on the main board of the Hong Kong Stock Exchange. The company's pipeline includes advanced vaccine technologies. Notably, Fosun Adgenvax has been involved in the strategic collaboration between its parent company, Fosun Pharma, and BioNTech, which began in March 2020 to develop and commercialize a COVID-19 mRNA vaccine. This partnership led to clinical trials and subsequent distribution of the mRNA vaccine in Hong Kong SAR, Macau SAR, and the Taiwan region. In addition to its work with mRNA technology, Fosun Adgenvax is independently developing other vaccines, such as a 13-valent pneumococcal conjugate vaccine for the prevention of pneumococcal infections. Fosun Adgenvax is positioned to leverage its parent company's extensive global network and resources. Fosun Pharma was founded in 1994 and has grown into a global pharmaceutical and healthcare group with operations in research, manufacturing, medical devices, and healthcare services. Recent activities for Fosun Adgenvax include securing a capital increase of approximately RMB 968 million to expand its R&D pipeline, enhance production capabilities, and support the commercialization of its products. The company has also obtained a Drug Manufacturing Licence and a Drug Operation Licence, crucial steps for the commercial sale of its vaccine products.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2012
Headquarters
Chengdu, China
Open positions
None listed
Dealroom signal
20.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Drug Development, Vaccines, Became $1B as Subsidiary, mRNA Medicines
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jun 2026 $133M $1.1B Undisclosed ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Fosun Antekin in the Chengdu ecosystem

Live from Dealroom

The Fosun Antekin office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Chengdu HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Fosun Antekin on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Fosun Antekin’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.